| Withdrawn | A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Blad Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder | Phase 3 | 2026-06-30 |
| Not Yet Recruiting | A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder C Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder | Phase 3 | 2026-06-01 |
| Withdrawn | A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NM Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder | Phase 3 | 2026-05-01 |
| Recruiting | Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC Non Muscle Invasive Bladder Cancer | Phase 2 | 2024-08-01 |
| Completed | A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) Major Depressive Disorder | Phase 3 | 2021-06-02 |
| Completed | Safety of REL-1017 for Major Depressive Disorder Major Depressive Disorder | Phase 3 | 2021-04-01 |
| Completed | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (M Major Depressive Disorder | Phase 3 | 2021-01-08 |
| Completed | Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant | Phase 2 | 2018-05-11 |
| Completed | Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone) Neuropathic Pain | Phase 1 | 2015-08-31 |
| Completed | Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone) Neuropathic Pain | Phase 1 | 2014-12-04 |
| Temporarily Not Available | Individual Patient Esmethadone (REL-1017) Expanded Access Program Major Depressive Disorder, Depression | — | — |